Efficacy and Safety of Messenger RNA Vaccines

Background and Aims The rapid development of mRNA vaccines has revolutionized infectious disease prevention and cancer immunotherapy. While their efficacy is well established, concerns about safety and immunopathological risks persist. This study aims to evaluate the immunogenicity, safety profiles, and design considerations of mRNA vaccines to optimize their protective benefits while minimizing adverse effects. Methods A comprehensive literature review was conducted, including clinical trials, preclinical studies, and pharmacovigilance reports from 2015 to 2025, focusing on vaccine mechanisms, immune responses, and safety outcomes. Results mRNA vaccines utilize lipid nanoparticles (LNPs) for delivery, effectively inducing robust humoral and cellular immunity. Clinical data reveal high protection levels, but rare adverse effects such as vascular inflammation, myocarditis, and autoimmune phenomena have been reported. Achieving an optimal balance between strong immune activation and tolerability remains a key challenge. Ongoing research explores personalized vaccine strategies, improved delivery systems, and advanced safety surveillance to address individual variability and long‐term safety. Conclusion mRNA vaccine technology offers unparalleled flexibility and potency, with a promising safety profile when carefully optimized. Continued technological refinement, personalized approaches, and vigilant safety monitoring are essential to fully harness its potential. Responsible innovation will be pivotal in advancing mRNA platforms to meet global health challenges.